Oxatomide

This classification denotes a histamine-1 receptor antagonist with the molecular formula C27H30N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier J31IL9Z2EE, chemically known as 2h-benzimidazol-2-one, 1,3-dihydro-1-(3-(4-(diphenylmethyl)-1-piperazinyl)propyl)- but generally known as oxatomide, which bears US NIH Compound Identifier 4615. European Medicines Agency schedules Oxatomide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09504MIG. The term OXATOMIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 32, No 10 1978, List 18). World Health Organization schedules oxatomide in its Anatomical Therapeutic Chemical (ATC) Classification. OXATOMIDE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule oxatomide under HS 29335995 and SITC 51576. As of Q4 2014, OXATOMIDE remains the US FDA Preferred Term for this commodity. Oxatomide bears US NLM identifiers UMLS ID C0134337 and NCI Concept Code C73051. SMILES: O=C1N(CCCN2CCN(CC2)C(C2CCCCC2)C2CCCCC2)C2C([NH]1)CCCC2.